Segment, Customer and Geographical Reporting (Tables)

9 Months Ended

Jun. 30, 2013

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The Company’s segment information for the three months ended June 30, 2013 and 2012 is summarized below:

Results of Operations for the Three Months Ended June 30,
2013
	Contract Research		Optics		Instruments		Biomedical		Total
Revenue	$	5,933,085	$	3,860,648	$	1,498,609	$	30,000	$	11,322,342
Gross Profit		2,514,235		1,500,419		783,225		30,000		4,827,879
Impairment of goodwill & long-lived assets		-0-		-0-		-0-		-0-		-0-
Operating Income (Loss)		22,869		25,402		(48,219)		(215,559)		(215,507)
Depreciation and Amortization		88,770		191,741		163,715		15,000		459,226
Capital expenditures		-0-		206,898		-0-		-0-		206,898
Intangibles, Net		332,800		848,046		2,230,334		194,997		3,606,177
Goodwill		4,938,625		1,197,503		-0-		-0-		6,136,128
Total Assets	$	13,562,650	$	8,780,459	$	5,142,707	$	262,955	$	27,748,771

Results of Operations for the Three Months Ended June 30,
2012
	Contract Research		Optics		Instruments		Biomedical		Total
Revenue	$	6,473,078	$	4,157,751	$	1,443,756	$	7,452	$	12,082,037
Gross Profit		2,487,372		1,696,071		794,875		6,341		4,984,659
Operating Income (Loss)		202,551		336,112		(441,905)		(236,109)		(139,351)
Depreciation and Amortization		59,058		184,512		133,203		15,000		391,773
Capital expenditures		3,273		(35,156)		108,583		-0-		76,700
Intangibles, Net		375,467		388		5,255,067		255,000		5,885,922
Goodwill		4,938,625		2,049,611		6,299,571		-0-		13,287,807
Total Assets	$	13,895,142	$	11,351,634	$	14,916,226	$	309,461	$	40,472,463

The Company’s segment information for the nine months ended June 30, 2013 and 2012 is summarized below:

Results of Operations for the Nine Months Ended June 30,
2013
	Contract Research		Optics		Instruments		Biomedical		Total
Revenue	$	16,331,775	$	12,044,354	$	3,796,967	$	187,051	$	32,360,147
Gross Profit		7,376,158		4,832,981		1,850,127		187,051		14,246,317
Impairment of goodwill & long-lived assets		-0-		-0-		6,763,072		-0-		6,763,072
Operating Income (Loss)		254,278		413,414		(7,774,714)		(547,786)		(7,654,808)
Depreciation and Amortization		231,189		562,065		491,147		45,000		1,329,401
Capital expenditures		(1,095)		416,580		7,092		-0-		422,577
Intangibles, Net		332,800		848,046		2,230,334		194,997		3,606,177
Goodwill		4,938,625		1,197,503		-0-		-0-		6,136,128
Total Assets	$	13,562,650	$	8,780,459	$	5,142,707	$	262,955	$	27,748,771

Results of Operations for the Nine Months Ended June 30,
2012
	Contract Research		Optics		Instruments		Biomedical		Total
Revenue	$	19,677,334	$	11,754,515	$	5,056,540	$	24,953	$	36,513,342
Gross Profit		7,699,303		4,629,856		2,883,666		(16,875)		15,195,950
Operating Income (Loss)		506,046		531,205		(901,357)		(688,633)		(552,739)
Depreciation and Amortization		153,995		533,612		402,359		45,000		1,134,966
Capital expenditures		350,492		289,685		123,851		-0-		764,028
Intangibles, Net		375,467		388		5,255,067		255,000		5,885,922
Goodwill		4,938,625		2,049,611		6,299,571		-0-		13,287,807
Total Assets	$	13,895,142	$	11,351,634	$	14,916,226	$	309,461	$	40,472,463

Schedule Of Segment Revenue By Geographical Location [Table Text Block]

Revenue by geographic location in total and as a percentage of total revenue, for the three months ended June 30, 2013 and 2012 are as follows:

	Three Months Ended					Three Months Ended
	June 30, 2013					June 30, 2012
Geographic Location	Revenue		% of Total			Revenue		% of Total
United States	$	9,426,542		83	%	$	10,130,936		84	%
Europe		975,941		9	%		981,147		8	%
Other		919,859		8	%		969,954		8	%
	$	11,322,342		100	%	$	12,082,037		100	%

Revenue by geographic location in total and as a percentage of total revenue, for the nine months ended June 30, 2013 and 2012 are as follows:

	Nine Months Ended					Nine Months Ended
	June 30, 2013					June 30, 2012
Geographic Location	Revenue		% of Total			Revenue		% of Total
United States	$	26,493,062		82	%	$	30,446,812		83	%
Europe		2,711,944		8	%		3,210,520		9	%
Other		3,155,141		10	%		2,856,010		8	%
	$	32,360,147		100	%	$	36,513,342		100	%